We are live on
!
Find out more
AG
Artal Group Portfolio holdings
AUM
$1.01B
1-Year Est. Return
29.84%
This Fund
S&P 500
This Quarter
Est. Return
+37.32%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$1.01B
AUM Growth
+$296M
(+41%)
Cap. Flow
+$27M
Cap. Flow
% of AUM
2.67%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
2
New
–
Increased
1
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lexicon Pharmaceuticals
LXRX
|
+$27M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 76.11% |
| 2 | Healthcare | 23.89% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
CAVA Group
CAVA
$7.22B
| $769M | 76.11% |
9,507,990
| – | – |
|
|
2
Lexicon Pharmaceuticals
LXRX
$1.02B
| $241M | 23.89% |
154,734,327
+18,553,846
| +14% | +$27M |
|
Similar funds
BCM
GA
EPAM
WA
CT
AH
LPAM
PIM
Artal Group's Q1 2026 Portfolio in Review
As of Q1 2026, Artal Group held 2 positions worth $1.01B, up 41% from $715M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Trading was light in Q1 2026: portfolio turnover was 0%. Artal Group opened no new positions and made no exits, leaving the 2-position portfolio largely intact.
By sector, the portfolio is most concentrated in Consumer Discretionary at 76% of assets, down from 78% a quarter earlier, followed by Healthcare.
- Artal Group added most to Lexicon Pharmaceuticals in Q1 2026, an estimated $27M increase.
- Artal Group's ten largest holdings make up 100% of its $1.01B portfolio in Q1 2026.
- Artal Group opened 0 new positions and closed 0 in Q1 2026.
- Artal Group's portfolio value rose 41% quarter-over-quarter to $1.01B.
Based on Artal Group's 13F filing for Q1 2026, filed 14 May 2026.